Clinical Trials List
2019-10-24 - 2021-03-08
Phase III
Terminated1
ICD-10C50
Malignant neoplasm of breast
ICD-10M41.20
Other idiopathic scoliosis, site unspecified
ICD-10J45
Asthma
ICD-10J15.8
Pneumonia due to other specified bacteria
ICD-10J44.9
Chronic obstructive pulmonary disease, unspecified
ICD-10J15.20
Pneumonia due to staphylococcus, unspecified
ICD-9157.9
Malignant neoplasm of pancreas, part unspecified
-
-
Trial Applicant
QPS
-
Sponsor
-
-
Trial scale
Taiwan Multiple Center
-
Update
2026/05/15
Investigators and Locations
Co-Principal Investigator
- Chi-Lu Chiang Division of Hematology & Oncology
- I-Cheng Lee Digestive System Department
- Yi-Ping Hung Division of Hematology & Oncology
- Tien-Hua Chen Division of Hematology & Oncology
- Hsu-ching Huang Division of Hematology & Oncology
- Hao-Wei Teng Division of Hematology & Oncology
- Ling-Ming Tseng 未分科
- 李癸汌 Digestive System Department
- 姜乃榕 Division of Hematology & Oncology
- Mu-Hsin Chang Division of Hematology & Oncology
- 陳宥任 Digestive System Department
- 廖映庭 Division of Hematology & Oncology
- Yung-Hung Luo Division of Hematology & Oncology
- 呂學聖 Digestive System Department
- Chia-I Shen Division of Hematology & Oncology
- 唐振育 Division of Hematology & Oncology
- Ming-Huang Chen Division of Hematology & Oncology
- Muh-Hwa Yang Division of Hematology & Oncology
- Yun-Cheng Hsieh Digestive System Department
- Hung-Yuan Yu Digestive System Department
- Chung-Pin Li Division of Others -
- Chien-An Liu Division of Radiology
- Shao-Jung Hsu Digestive System Department
- YEN-HAN TSENG Division of Hematology & Oncology
- 齊振達 Digestive System Department
Audit
None
Co-Principal Investigator
- Chao-Chun Yang 未分科
Audit
None
Co-Principal Investigator
Audit
None
Co-Principal Investigator
- Jih-Hsiang Lee Division of Hematology & Oncology
- 吳宗哲 Division of Hematology & Oncology
- 徐偉勛
- SHIH-HUNG YANG Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
42 participants
-
Global
42 participants
